Progesterone Receptor Negative Recruiting Phase 2 Trials for Ifetroban (DB12321)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03694249Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic RecurrenceTreatment